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The glucose-regulated protein94 (Grp94) has been found in complexes with IgG in plasma of Type 1 (T1) diabetic subjects; however,
the pathogenetic meaning of Grp94-IgG complexes has not yet been elucidated. To shed light on the nature and structure of these
complexes in vivo, we conducted a proteomic analysis on plasma of both T1 diabetic subjects and healthy control subjects. IgG
purified from plasma was submitted to 2D PAGE followed by Western blotting and mass analysis. Grp94 was detected in plasma
of all diabetic but not control subjects and found linked with its N-terminus to the IgG heavy chain. Mass analysis of heavy chain
of IgG that binds Grp94 also in vitro, forming stable complexes with characteristics similar to those of native ones, permitted
identifying CH2 and CH3 regions as those involved in binding Grp94. At the electron microscopy, IgG from diabetic plasma
appeared as fibrils of various lengthes and dimensions, suggestive of elevated aggregating tendency conferred to IgG by Grp94.The
nonimmune nature of complexes turned out to be responsible for the particular stability and structure adopted by complexes in
plasma of diabetic subjects. Results are of relevance to understanding the pathogenetic mechanisms underlying diabetes and its
complications.
1. Introduction
Previous studies indicated that plasma of T1 diabetic subjects
contains elevated concentrations of the heat shock protein
(HSP) glucose-regulated protein94 (Grp94) [1, 2]. Besides the
chaperone function shared with other HSPs, Grp94 displays
unique immune-regulatory activity by loading antigens onto
molecules of the MHC system for presentation to immune
competent cells [3, 4]. Since HSPs are obligatory intracellular,
extracellular Grp94 always represents an immunological
danger [5, 6] and is an index of altered cell membrane perme-
ability that precedes and accompanies diverse inflammatory
and immunological processes [7].
In plasma of T1 diabetic patients Grp94 does not circulate
as free protein but always binds to IgG, forming stable
complexes that have been interpreted as immune in nature
[1, 2]. This was also supported by the finding that anti-Grp94
antibodies are present in diabetic plasma in response to the
immune stimulation driven by extracellular Grp94 [2]. Other
observations indicated that Grp94-IgG complexes in diabetic
plasma can induce an intense activation of inflammatory cell
signaling pathways with angiogenic-like transformation of
vascular cells [8].This has led to the proposal that Grp94-IgG
complexes might be a marker of increased risk of vascular
complications in T1 diabetes [2]. However, studies showing
that Grp94 is able to form stable complexes with IgG also
in vitro and that these complexes partly mimic the effects
provoked by native complexes [9] raised the possibility that
also in vivo Grp94 might form nonimmune complexes with
IgG. If actually proved, the nonimmune nature of Grp94-
IgG complexes could shed new light on the pathogenetic
mechanisms associated with diabetes and its complications.
To address the specific issue of the nature of Grp94-IgG
complexes and also to define the structure that complexes
might adopt in vivo, we conducted an in-depth proteomic
analysis and microscopic investigation on IgG purified from
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plasma of both diabetic and healthy control subjects. Our
results let elucidate how the nonimmune binding engaged
by Grp94 with IgG in vivo is responsible for the formation
of complexes that for the particular stability and long persis-
tence in circulation might drive adverse biological effects.
2. Materials and Methods
2.1. Participants in the Study. The study protocol was
approved by Local Ethics Committee and both patients and
healthy subjects gave their informed written consent for
having blood sample (15mL) taken in fasting conditions. Ten
(5 males and 5 females) age-matched, fasting T1 diabetic
patients were recruited among those attending the Center
of Metabolic Diseases SOC (Hospital of Rovigo) during
their routine visits for checking diabetes status. The mean
age (±SD) of diabetic patients was 30.5 (±9.57) yr, their age
at onset of diabetes 16.5 (±7.41) yr, and diabetes duration
13.9 (±7.46) yr. The patient whose plasma was also analyzed
individually was a 26-year-old male who developed diabetes
at the age of 11 yr. Eight (4 males and 4 females) nonsmokers
volunteers with mean age (±SD) of 35.4 (±8.2) yr served as
control.
2.2. IgG Purification from Plasma. Plasma was obtained after
centrifugation of individual blood sample and dialyzed. An
equal content of proteins of any plasma sample (0.9mg
proteins) served to form the pool of plasmas, and 1.0mg
proteins of pooled plasma were loaded onto a mono-Q HR
5/5 column (Amersham Biosciences, Uppsala, Sweden), as
described in [10]. IgG eluted in the first two peaks that were
then collected and loaded onto a 1mL HiTrap Protein G
HP column for further purification. The whole IgG eluted
at the flow rate of 0.5mL/min in the second peak with
the eluent B (0.1M glycine buffer, pH 2.5) and acidity was
immediately buffered (1.0M Tris-HCl pH 9.0) to prevent
protein denaturation. The IgG peak was ultrafiltered on
Amicon Centriplus YM-3 and proteins measured by BCA
protein assay. The same procedure was applied to obtain
purified IgG from individual diabetic plasma sample.
2.3. Analysis on Grp94-IgG Complex Formed In Vitro. In
separate experiments, recombinant rabbit Grp94 was used to
form complexes with human IgG, following the procedure
detailed previously [11]. Briefly, Grp94 was incubated with
IgG at the molar ratio of 1 : 2, and after incubation at 37∘C
for 2 h, the complex formation was evaluated in native
PAGE by loading 5 𝜇g proteins onto 8.5% polyacrylamide
gel, followed by Western blotting for detecting Grp94. The
complex solution was then submitted to MS analysis.
2.4. Electrophoresis and Western Blot Analyses. SDS-PAGE
was performed on 10% polyacrylamide gel and samples (7–
10 𝜇g proteins) were loaded either with or without reducing
treatment, as specified in the figure legends. Gels were stained
with Coomassie Brilliant Blue. ForWestern blotting, proteins
were transferred into a PVDF membrane (Immobilon P,
Millipore, Bellerica, MA, USA) and treated with anti-human
Grp94 monoclonal (9G10 clone) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and sheep anti-human whole IgG
antibodies (Abs) (Bethyl Laboratories, Inc., Montgomery,
TX, USA). For 2D-PAGE, 41.5 𝜇g IgG were diluted to 1.0mL
with 0.1M Tris-HCl, 1.0mM EDTA, and 6.0M guanidine
at pH 8.3 and submitted to extensive reduction with DTT
and carboxymethylation with iodoacetic acid according to
Allen [12] followed by thorough dialysis against water. The
IgG solution was then brought to dryness in SpeedVac and
dissolved in 5.0mM Trizma base, 9.0M urea, 2% (w/v)
CHAPS, and 0.2% (w/v) ampholyte, with pH range 3–10. IEF
was carried out on 3–10 pH range 11 cm IEF strips for 35,000V
× h at 4∘C. Focusing strips were then incubated in 0.375M
Tris-HCl pH 8.8, 2% (w/v) SDS, 6.0M urea, and 20% (v/v)
glycerol for 20min, immediately loaded at the top of 12% SDS
gels, covered with Laemmli reducing sample buffer and run
in a stepwise manner at 5mA/strip for 1 hour, 10mA/strip for
1 hour, and 20mA/strip for 3 hours. The SDS gels were either
stained with Colloidal Coomassie blue or used for Western
blotting.
2.5. In-Gel Protein Digestion. Following Western blotting,
spots of the proteins of interest were excised from the gel
stained with Colloidal Coomassie after SDS-PAGE, and gel
pieces destained twice in 0.2M ammonium bicarbonate,
40% (v/v) acetonitrile at 37∘C, and dehydrated with 100%
acetonitrile and brought to dryness in SpeedVac. Rehydration
of gel pieces was performed on ice in a minimal volume
of 40mM ammonium bicarbonate and 10% (v/v) acetoni-
trile pH 8.0 containing 0.4 𝜇g trypsin (Trypsin Gold, Mass
Spectrometry grade, PROMEGA). Digestion was performed
overnight at 37∘C. After incubation, peptides were recovered
and transferred into a new tube. The sample mixture from
each gel piece was thus brought to dryness in SpeedVac and
resuspended into aminimal volume of 0.1% (w/v) formic acid
for subsequent MS analysis.
2.6.MSAnalysis. Samples fromdigested gel spotswere run in
an LTQ-Orbitrap XL mass spectrometer (Thermo Scientific)
coupledwith a nano-HPLCUltimate 3000 (Dionex). Peptides
were loaded onto a homemade picofrit column packed with
C18 material and separated using a 45min linear gradient of
acetonitrile/0.1% formic acid (from 0% to 40% acetonitrile in
25min), at a flow rate of 250 nl/min. Capillary voltage was set
at around 1.3–1.5 kV and source temperature at 200∘C. For
identification experiments, the instrument was operating in
a data-dependent mode according to a full scan at 60,000
resolution on the Orbitrap, followed by 10MS/MS scans on
the most intense ions in the linear trap.
2.7. Analysis of Data. Raw data were visualized and exported
into .xml format with the Protein Identification software
BioWorks rev. 3.3.1 SP1 (Thermo Fisher Scientific Inc.,
Waltham,MAUSA) for subsequent databasemining.MS/MS
dataset was searched with Mascot search engine with in-
house server version of Mascot rev. 2.3 (Matrix Science)
against ad hoc built database for 94 kDa glucose-regulated
protein (SwissProt, entry P14625, and O18750) and against
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the whole SwissProt database with no taxonomy restriction.
Search constraints were 10 ppm tolerance for precursor ion
masses and 0.6Da tolerance for fragment ion masses. No
enzyme restriction specificity was imposed for peptide, and
cysteine residues were assumed to be carboxymethylated
in samples from 2D-PAGE, while deamidation on argi-
nine/glutamine, oxidation on methionine, and acrylamide
adduct on cysteine were selected as possible modifications.
2.8. Electron Microscopy Analysis. Plasma-purified IgG solu-
tions were used at the final concentration of 0.09mg/mL. An
aliquot of each sample was absorbed onto glow-discharged
carbon-coated Butvar films on 400-mesh copper grids. The
grids were negatively stained with an unbuffered solution of
1% uranyl acetate and observed at the microscope (Tecnai
G12, Fei Company, Eindhoven, Holland). For each sample,
several pictureswere taken in separate sections of the grid and
those representative of at least two measurements performed
on different occasions were presented.
3. Results
3.1. Grp94 Is Bound to IgG Heavy Chain of Diabetic Subjects.
Any individual plasma and pooled plasma of diabetic and
control subjects were first analyzed in Western blotting to
assess positivity for Grp94. No immune reaction for Grp94
was shown in control plasma (data not shown), whereas
an intense positivity was detected in any diabetic plasma,
although with some interindividual difference (Figure 1).The
highmolecular mass at which Grp94 focused in nonreducing
conditions of SDS-PAGE was consistent with the formation
of complexes with IgG, as assessed by copositivity for IgG
in the same Grp94-positive bands (data not shown). 2D
SDS-PAGE was performed in parallel on the IgG fraction
purified from pooled plasma of both diabetic and control
subjects (Figure 2) to detect differences in charge density
and/or composition of IgG, and to identify the IgG subunit
involved in binding Grp94. The same analysis was also
conducted on individual plasma that showed the highest
concentration of Grp94 (Figure 1, patient #1). IgG of diabetic
and control subjects had similar isoelectric focusing and
distribution pattern of IgG subunits in terms of molecular
masses. Grp94 was not found in any IgG subunits of control
subjects, whereas it was detected in the 50 kDa band of IgG
of both pooled and individual diabetic plasmas (Figure 2). In
pooled plasma, Grp94 focused on a single spot at acidic pH,
likely due to overwhelming contribution of more negatively
charged IgG of some patient(s) in the pool, whereas in
individual plasma Grp94 focused on a wider range of pH
with a higher intensity of the immune reaction. The different
distribution pattern of IgG-linked Grp94 was consistent with
the observed interindividual variability in the quantity and
qualitative characteristics of circulating Grp94-IgG com-
plexes [2]. Results proved that part of Grp94 was still strongly
bound to the 50 kDa IgG subunit althoughmost part of it was
lost during the extensive denaturation of samples for 2D SDS-
PAGE.
Grp94 in diabetic plasma (pooled and individual)
Pooled
plasma
Diabetic subjects
(kDa)
150
100
IO
D
 (a
.u
.)
200
100
0
#1∗ #2 #3 #4 #5 #6 #7 #8 #9 #10
Figure 1: Grp94 is detected in plasma of diabetic subjects. Plasma
samples were processed as described in Section 2, and 7.5 𝜇g proteins
of each sample loaded onto a 10% polyacrylamide gel without
reducing treatment. Pooled plasmawas obtained bymixing an equal
protein content of any single plasma sample. Proteins were blotted
onto a PVDF membrane and probed with anti-Grp94 Abs. Cross-
reactivity for secondary anti-human Abs was excluded by exposing
themembrane to secondary Abs before the incubation with primary
Abs. Densitometric analysis of Grp94-positive bands is reported
below (IOD, integrated optical density). ∗Subject whose plasma was
also analyzed separately.
3.2. N-Terminal Region of Grp94 Is Bound to IgGHeavy Chain.
Several spots of IgG bands, of both control and diabetic
plasma, including bands positive for Grp94 at 50 kDa, were
excised from gels of 2D PAGE and digested for ESI-MS
analysis. Analysis showed that bands at both 100 and 50 kDa
contained IgG heavy (𝛾) chain and those at 25 kDa light (𝑘)
chains (data not shown). No sequence pertaining to Grp94
was found in any IgG band of control plasma and also in
the 50 kDa IgG band of pooled diabetic plasma although
Western blotting proved the presence of Grp94 (Figure 2).
This was likely due to the small quantity of Grp94 in the
spot, insufficient for being detected in mass analysis. Indeed,
in the IgG heavy chain of individual plasma with a more
intense positivity for Grp94, mass analysis identified nine
unique peptides (Figure 3(a)) comprised between the amino
acid residues 63 and 201 in the N-terminal region of human
Grp94 (Figure 3(b)). Intriguingly, only one peptide was
produced by trypsin cleavage, whereas others were formed
by a nonspecific, probably autoproteolytic mechanism. This
finding suggested that sites of proteolytic attack in Grp94
were not accessible to trypsin, probably for steric hindrance
due to IgG binding.
Mass analysis of Grp94-positive heavy chain did not
permit identifying the site in IgG specifically involved in
binding Gp94, since tryptic digestion of the heavy chain
yielded peptides that always matched those of control IgG
heavy chain (data not shown). However, this negative result
was somehow expected given the large excess of Grp94-
free IgG that rendered any signal due to Grp94-bound IgG
undetectable.
3.3. CH2 and CH3 Regions of IgG Involved in Binding to
Grp94 In Vitro. To overcome the difficulty to identify the
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Figure 2:Grp94 is linked to the IgGheavy chain. Panels show 2DSDS-PAGEof the IgG fraction purified fromplasma of both diabetic (pooled
and single plasma) (upper and central panels, resp.) and healthy control subjects (pooled plasma, lower panels). Protein concentration was
measured with the BCA protein assay and 41.5𝜇g proteins of each sample were loaded in the gel. Correctness of the protein loading was
assessed by prior explorative SDS-PAGE. 2D SDS-PAGE of each sample was conducted in duplicate: one gel was used for mass analysis and
the other blotted and probed with anti-Grp94 Abs and then with anti-IgG biotin-conjugated Abs followed by exposure to HRP-conjugated
streptavidin. After stripping, the membrane was exposed to anti-human IgG primary Abs followed by incubation with HRP-conjugated
secondary Abs. Horizontal and vertical arrows indicate, respectively, the range of pH (3–10) at which sample proteins focused in the first
iso-focusing PAGE and the direction of the run (from the cathode to the anode) in the second dimension SDS-PAGE. Circled are parts of
IgG bands, including those positive for Grp94, excised for mass analysis.
portion of the IgG heavy chain involved in binding Grp94
in vivo, we took the advantage of the analysis performed on
complexes that Grp94 can also form in vitrowith human IgG
[9]. In previous works we demonstrated that these complexes
have properties that partly overlap those displayed by native
ones, being also characterized by an irreversible binding
that confers on these complexes a particular resistance to
tryptic digestion [11]. Taking into consideration these results
and the finding that in diabetic plasma Grp94 is linked to
IgG heavy chain (Figure 2), we hypothesized that also in
complexes formed in vitro the binding could occur in the
same region of IgG. Thus, by investigating in vitro formed
Grp94-IgG complexes it was possible tomake inference about
the IgG region involved in Grp94 binding also in vivo. To
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1 MRALWVLGLC CVLLTFGSVR ADDEVDVDGT VEEDLGKSRE GSRTDDEVVQ
51 REEEAIQLDG LNASQIRELR EKSEKFAFQA EVNRMMKLII NSLYKNKEIF
101 LRELISNASD ALDKIRLISL TDENALSGNE ELTVKIKCDK EKNLLHVTDT
151 GVGMTREELV KNLGTIAKSG TSEFLNKMTE AQEDGQSTSE LIGQFGVGFY
201 SAFLVADKVI VTSKHNNDTQ HIWESDSNEF SVIADPRGNT LGRGTTITLV
251 LKEEASDYLE LDTIKNLVKK YSQFINFPIY VWSSKTETVE EPMEEEEAAK
301 EEKEESDDEA AVEEEEEEKK PKTKKVEKTV WDWELMNDIK PIWQRPSKEV
351 EEDEYKAFYK SFSKESDDPM AYIHFTAEGE VTFKSILFVP TSAPRGLFDE
401 YGSKKSDYIK LYVRRVFITD DFHDMMPKYL NFVKGVVDSD DLPLNVSRET
451 LQQHKLLKVI RKKLVRKTLD MIKKIADDKY NDTFWKEFGT NIKLGVIEDH
501 SNRTRLAKLL RFQSSHHPTD ITSLDQYVER MKEKQDKIYF MAGSSRKEAE
551 SSPFVERLLK KGYEVIYLTE PVDEYCIQAL PEFDGKRFQN VAKEGVKFDE
601 SEKTKESREA VEKEFEPLLN WMKDKALKDK IEKAVVSQRL TESPCALVAS
651 QYGWSGNMER IMKAQAYQTG KDISTNYYAS QKKTFEINPR HPLIRDMLRR
701 IKEDEDDKTV LDLAVVLFET ATLRSGYLLP DTKAYGDRIE RMLRLSLNID
751 PDAKVEEEPE EEPEETAEDT TEDTEQDEDE EMDVGTDEEE ETAKESTAEK
801 DEL
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71 VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP
111 PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS
111 PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS
151 HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT 
151 HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT 
191 VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ
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Figure 3: Identification of sites of binding in both Grp94 and IgG. (a) Nine unique peptides mapping the N-terminal region of human Grp94
were obtained after digestion of spots at about 50 kDa in bands positive for both Grp94 and IgG (evidenced in Figure 2) and submitted to
ESI-mass analysis. Only one peptide was produced by trypsin digestion, whereas others might be due to autoproteolytic cleavage. Calculated
molecularmass of each peptide is reported near the corresponding sequence. ∗Aminoacid residue deamidated. (b) Sequence of humanGrp94
(Hsp90 B1, Swiss Prot entry P14625). Sequences corresponding to the observed peptides are grey boxed. More than one peptide is found to
match the boxed sequences (indicated by double arrow lines below the sequence). (c) Western blotting for both Grp94 and IgG of human
IgG and recombinant rabbit Grp94 incubated both alone (control) and together at the final molar concentration of 2 : 1 to form Grp94-IgG
complexes, as specified in Section 2. Five 𝜇g IgG and 1.3𝜇g Grp94 were loaded onto 10% polyacrylamide gel after reducing treatment of
samples. After blotting, the membrane was first exposed to monoclonal anti-Grp94 Abs and then, after stripping, to anti-human IgG Abs.
The immune reaction was detected as specified in the legend to Figure 2.The arrow on the left indicates the 50 kDa band excised from the gel
of SDS-PAGE for mass analysis and found positive for Grp94. No immune reaction at 50 kDa was found in control Grp94. (d) Human IGHG1
amino acid sequence containing CH1 (residues 1–98), hinge (residues 99–110), CH2 (residues 111–223), and CH3 regions (residues 254–275)
in both control IgG and IgG + Grp94. Coverage of the Ig 𝛾-1 chain C for both sample was highly reproducible. Peptides identified in both
samples are boxed in grey, whereas the missing sequences in IgG + Grp94 are in clear boxes. Empty arrows indicate the cleavage points by
trypsin. Arrows on right indicate that the coverage sequence extends to the following residues.
this aim, mass analysis was conducted on heavy chain of
human IgG incubated both alone and with recombinant
rabbit Grp94, used as relevant substitute of human Grp94 to
form nonimmune complexes [11]. Since in these experiments
we used stoichiometric quantities of Grp94 and IgG, it was
not necessary to submit samples to 2D-PAGE to separate
IgG subunits that were easily evidenced by analyzing samples
in reducing conditions in SDS-PAGE followed by Western
blotting (Figure 3(c)). Thus, by probing samples with both
anti-IgG and anti-Grp94 Abs, we noted that the 50 kDa
band of IgG incubated with Grp94 was also positive for
Grp94 (Figure 3(c)). Since control Grp94 did not migrate at
50 kDa, this result indicated thatGrp94was closely associated
with IgG, similarly to what was observed in diabetic plasma
(Figure 2). Mass analysis of 50 kDa bands of both control
IgG and IgG incubated with Grp94 confirmed the presence
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Control subjects
(pooled plasma)
Diabetic subjects
(pooled plasma)
Diabetic subject
(individual plasma)
100nm
Figure 4: Electron microscopy of IgG purified from both pooled and single diabetic plasma and from pooled control plasma. Two
representative images, taken from different fields in the same or separate pictures, are shown for each sample and treated as specified in
Section 2. Homogeneous carpet of IgG distributed in overlapping layers with rare aggregates was the common feature of the control sample,
whereas filaments of various dimensions were the characteristic shape adopted by IgG in diabetic plasma. Calibration bar is below images.
of IgG 𝛾-1 chain C region in both samples (Figure 3(d),
overlapping peptides that are grey boxed). However, in the
heavy chain of Grp94-IgG complex, two long peptides:
139TPEVTCVVVDVSHEDPEVK in the CH2 region and
254GFYPSDIAVEW-ESNGQPENNYK in the CH3 region
were missing (Figure 3(d), residues in clear boxes). The lack
of coverage of these sequenceswas consistentwith being these
regions of IgG involved in binding toGrp94 so that the tryptic
cleavage at 138R and 253K yielded peptides that did not match
any known IgG sequences deposited in the data banks.
3.4. Electronic Visualization of Grp94-IgG Complexes in Dia-
betic Plasma. Since complexes that Grp94 forms with IgG in
vitro can reach big dimensions [11], we asked whether also
complexes circulating in diabetic plasma could be visualized
at the electronic microscopy. We thus analyzed IgG of both
pooled and individual diabetic plasma and those of control
subjects at the electronic microscopy. A dense carpet of
IgG molecules, locally aggregated in isolated complexes and
characterized by well-known epsilon shape, was the common
feature of control plasma, whereas numerous filaments of
variable lengths (from few nm up to 100 nm) populated some
picture of pooled diabetic plasma (Figure 4). Even bigger and
longer filaments (up to 1 𝜇m) were present in individual dia-
betic plasma in which fibrils looked like amyloid formations.
Although differences in the length and dimension appeared
between pooled and individual plasma, fibril formationswere
the hallmark of any diabetic plasma supporting the possibility
that the particular aggregating tendency of IgG was the
consequence of the complex formation with Grp94.
4. Discussion
In this work we wanted to address the unsolved question
concerning the nature and structure of Grp94-IgG complexes
that circulate in plasma of T1 diabetic subjects with still
uncertain pathogenetic significance. Previous observations
suggested that these complexes could be immune in nature,
based on the finding that anti-Grp94 Abs were present in dia-
betic plasma in response to extracellular exposure of Grp94
[8]. However, the discovery that Grp94 was able to form
rapidly stable complexes also with nonimmune IgG in vitro
[9] raised the possibility that the mechanism leading to the
formation of Grp94-IgG complexes in vivo could also exclude
an antigenic recognition. In this view, Grp94 that enters
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circulation following autoimmune cell damage is expected
to bind rapidly to nonimmune IgG available in large excess
in plasma and form stable complexes that, thanks to their
stability, might acquire immunogenic properties [9]. Thus,
the complexes that Grp94 forms firstmight be nonimmune in
nature, whereas immune ones appear later in response to the
immune stimulationmostly exerted byGrp94 in nonimmune
complexes. Our present results support the possibility that
Grp94-IgG complexes are actually nonimmune in nature,
since mass analysis conducted on IgG purified from diabetic
plasma demonstrated that Grp94 was inextricably linked to
IgG heavy chain, whereas Grp94 was never found in the IgG
light-chain, a result that permitted excluding that the antigen-
binding site of IgG is involved in the binding to Grp94. The
failure to detect immune Grp94-IgG complexes does not
negate the presence of these complexes in the circulation
rather it means that only the binding engaged in nonimmune
complexes is so strong to survive the drastic procedures
to which plasma samples are submitted for mass analysis,
whereas reversibility of the antigen-antibody binding does
not permit rescuing immune complexes.
Interestingly, we found Grp94 linked to IgG heavy chain
in any diabetic plasma, both individual and pooled (Figure 2),
although mass analysis identified the peptides of the N-
terminus of Grp94 only in plasma of the diabetic subject with
the most intense expression of Grp94. The plausible expla-
nation of this result is that, in the pool of plasmas in which
any patient gave his/her own variable contribution of Grp94
(Figure 1), the resulting concentration of Grp94 was too low
to permit the detection of any Grp94 fragment, considering
also the loss of Grp94 due to the drastic conditions used in
the mass analysis.
The overwhelming concentration of Grp94-free over
Grp94-bound IgG in diabetic plasmas prevented us from
identifying the specific portion of the IgG heavy chain
engaged in binding to Grp94. However, we circumvented
this obstacle by taking advantage of previous observations
showing thatGrp94 can formcomplexeswith IgG also in vitro
[9]. The results of mass analysis demonstrating that Grp94
is linked to IgG heavy chain with the N-terminal region
(Figure 3(a)) were in line with previous results showing that
the N-fragment of Grp94 was per se sufficient to establish
the binding to IgG in vitro [11]. This gave support to the
assumption that the reaction of binding occurring in non-
immune Grp94-IgG complexes in vitro might be the same
that takes place in vivo.Thus, complexes formed in vitro could
be a reliable substitute of native ones for giving information
about the region of IgG involved in binding. This approach
permitted us to identify in CH2 and CH3 regions of the IgG
heavy chain the peptide sequences specifically involved in
binding Grp94 (Figure 3(d)) and to extend this result to the
IgG heavy chain of native complexes.
The stability and elevated aggregating tendency of cir-
culating Grp94-IgG complexes predicted by results of pro-
teomic analyses were further confirmed by the electron
microscopy analysis with the visualization of IgG that in
any diabetic, but not control plasma, appeared organized
in characteristic fibril formations of various lengthes and
dimensions (Figure 4). In individual plasma, fibrils were
bigger and longer than those seen in pooled plasma, a
difference likely attributable to the higher concentration
of Grp94 in individual plasma. However, regardless of the
dimension and shape, fibrils were the hallmark of any diabetic
plasma, pooled or single, and prove the pathological risk
linked to circulating Grp94-IgG complexes. Although we
have no direct proof that fibrils actually are the expression
of the aggregation capacity acquired by IgG in complexes
with Grp94, the alternative possibility that aggregation is due
to IgG glycation can reasonably be ruled out since glycation
necessary to induce an aggregation state of proteins should
have caused alterations in charge density and structure of IgG
that we instead failed to detect in both electrophoretic and
mass analyses.
In conclusion, our work has permitted to decipher the
nature and to show the shape of Grp94-IgG complexes
circulating in plasma of T1 diabetic subjects, demonstrating
that the exceptional stability and aggregating tendency of
these complexes are due to the binding that excludes the
immune recognition and involves the N-terminus of Grp94
and CH2 and CH3 regions in IgG heavy chain. Our results
convey important information about the role that Grp94-IgG
complexes might have in T1 diabetes: the bindingmechanism
leading to the formation of nonimmune complexes predicts
the rapidity at which complexes can form following the extra-
cellular liberation of Grp94 as well as their long persistence
in the circulation. The fact that aggregating complexes were
found in plasma of diabetic subjects with diabetes lasting for
years (see Section 2) testifies that Grp94 might be liberated
into the plasma even long after the onset of disease and that
Grp94-IgG complexes that thus form drive a risk of vascular
complications.
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